Lv1
50 积分 2024-04-23 加入
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
23天前
已完结
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors
1个月前
已完结
C-type natriuretic peptide and collagen X marker are aberrant in skeletal dysplasias
1个月前
已完结
Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
2个月前
已完结
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
3个月前
已完结
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
4个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
4个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
6个月前
已完结
皖公网安备34019202002308
